CHARLOTTE, N.C., April 24, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present the 12th Annual Needham Healthcare Conference at 10:40 AM on Wednesday, May 1, in New York.
Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a corporate update and an overview of the Northera (droxidopa) development program.
Mr. Oliveto's presentation will be webcast live and archived for 30 days on Chelsea's website, www.chelseatherapeutics.com.
About Chelsea Therapeutics
Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure.www.chelseatherapeutics.com.
Fara Berkowitz/Susan Kim